PF4 Antibody Persistence and Long-term Pathogenicity in VITT
Anand Padmanabhan, Professor and Consultant at Mayo Clinic, shared on LinkedIn:
”Congrats to Adam Kanack, Emily Mauch, Guillaume Roberge, and coauthors related to their study on long-term persistence and pathogenicity of VITT antibodies.
Key points:
– Despite clonal restriction of Anti-PF4 abs in VITT, unlike MGTS, these monoclonal spikes are not seen when the entire IgG repertoire is examined. You unmask anti-PF4 clonal restriction only when you isolate the anti-PF4 antibodies
– In some cases, VITT abs can comprise kappa light chains (dogma to date is that it can only be lambda)
– As shown in a case in our report, thrombocytopenia can persist for more than 4 years.”
Read the full article here.
Title: Platelet Factor 4 Antibody Persistence and Long-term Pathogenicity in Vaccine-induced Immune Thrombotic Thrombocytopenia
Authors: Adam Kanack, Emily Mauch, Guillaume Roberge, Noah Splinter, Krishna Gundabolu, Geoffrey D. Wool, Gemlyn George, Mouhamed Yazan Abou-Ismail, Kristi J. Smock, David L. Green, Jonathan Coker, Mindy C. Kohlhagen, David L. Murray, Anand Padmanabhan
Keep up with Hemostasis Today.
-
Jul 23, 2026, 19:17Diego López Santos: Donation after Donation, I Just Reached 100
-
Jul 23, 2026, 19:11Jecko Thachil: Chlorosis May Have Represented Iron Deficiency in the 19th Century
-
Jul 23, 2026, 15:58Mel Snyder: Beyond Sickle Cell Disease to the Future of Pediatric Genetics
-
Jul 23, 2026, 15:43Lorna Knight: The Next Frontier in Sickle Cell Disease Is Access
-
Jul 23, 2026, 15:29Ben Kleinstiver: Overcoming a Major Barrier to Scalable Gene Editing
-
Jul 23, 2026, 15:28Modernizing DIC Diagnosis in Cirrhosis: Building an International Registry for Precision Hemostasi
-
Jul 23, 2026, 14:32Saneha Anjum Shaikh: Why Antibody Screening Must Be Standard Practice in Modern Blood Banking
-
Jul 23, 2026, 14:00Ron Vezina: Canadian Blood Services Issues Urgent Donation Appeal
-
Jul 23, 2026, 13:46Sebastian Szmit: Understanding Troponins in Modern Cardio-Oncology